TYRA
Tyra Biosciences Inc
20.40$
-2.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | +100.0% | – | – | – | +22.7% | +51.9% | +22.0% | +28.0% | +7.8% | +18.8% | +0.0% | +1.2% | +3.6% | -4.7% | +24.4% | +19.6% | +3.3% | +0.8% | – | – | -2.1% | – | – | +4.5% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -130.5% | – | – | – | -157.7% | – | – | – | – | – | – | |
| – | +43.0% | +31.1% | +57.3% | +20.3% | +24.4% | +25.2% | +32.2% | +33.0% | +24.9% | -9.4% | -4.7% | +0.1% | +16.9% | +58.5% | +7.3% | -17.4% | +4.6% | +27.0% | -2.3% | +12.6% | -2.6% | +4.8% | +10.7% | +18.3% | +17.6% | – | |
| – | -11.0% | +14.1% | +59.4% | -8.0% | +63.6% | +2.4% | +132.4% | +93.5% | -34.8% | -19.3% | +69.2% | -15.0% | -1.9% | +21.8% | +5.6% | +3.3% | +8.1% | +6.7% | +28.1% | -9.0% | +3.7% | +4.6% | +11.4% | +2.4% | +15.0% | – | |
| – | +25.6% | +27.9% | +57.7% | +14.5% | +30.8% | +20.5% | +49.6% | +49.4% | +4.0% | -11.6% | +10.1% | -4.6% | +11.7% | +49.6% | +7.0% | -13.4% | +5.4% | +22.2% | +4.0% | +7.1% | -1.2% | +4.7% | +10.8% | +14.6% | +17.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | +4,225.0% | +226.9% | +30.6% | +66.1% | -99.1% | -76.2% | +48,980.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -99.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.